Jacobio Pharmaceuticals Co., Ltd.

Guiqun Yang

Mingming Chen

Lei Zhang

Tong Wu

Yanping Wang

Shaojing Hu

Qinglong Li

Haiquan Fang

Yuelei Du

Jun Tao

Haijun Li

Amin Li

Haiyan Yang

Hongling Wang

Qinghao Liu

Wenlai Zhou

Shanshan He

Dai Cheng

Provided is a binding molecule specific for LIF and use thereof. Specifically, provided is an isolated antibody or an antigen-binding fragment thereof that binds to LIF and inhibits the activity of LIF. Also provided are uses of the isolated antibody or the antigen-binding fragment thereof in treatment of diseases.

Binding molecule specific for LIF and use thereof

Disclosed are tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors which are shown as formula I, their synthesis and their use for treating diseases. More particularly, disclosed are fused heterocyclic derivatives useful as inhibitors of BET, methods for producing such compounds and methods for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.

Tricyclic compounds

Disclosed are tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors which are shown as formula I, their synthesis and their use for treating diseases. More particularly, disclosed are fused heterocyclic derivatives useful as inhibitors of BET, methods for producing such compounds and methods for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit. 

Provided are compounds of formula (I), or pharmaceutically acceptable salts thereof, which can be used for inhibiting the activity of Aurora A and treating cancer mediated by Aurora A. 

Heterocyclic compounds useful as aurora a selective inhibitors

Growing community of inventors

Beijing, China

Guiqun Yang